3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1/2
11
Phase 1
9
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
3
Skin Neoplasms
2
Carcinoma, Renal Cell
2
Neoplasm, Residual
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Interventions
Zoledronic Acid
5
Bevacizumab
3
exemestane
2
Therapeutics
2
Standard of Care
2
Pamidronate
2
Oxaliplatin
2
Misoprostol
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ibandronic Acid
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
vandetanib
1
palbociclib
1
liposomal doxorubicin
1
huaier
1
eribulin
1
enzalutamide
1
darolutamide
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Vindesine
1
Trastuzumab
1
Sugars
1
Stents
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasm Metastasis
×
aldesleukin
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts